Duesseldorf / Hannover / Dresden / Tuebingen / Rostock / Leipzig / Altstadt / Jena / Heidelberg / Hildesheim / Wiesbaden / Bonn / Magdeburg / Bremen / Hamburg / Helsinki / Frankfurt am Main / DRK City / Nuremberg / Berlin / Mannheim / Stuttgart / Regensburg / Gera / Staley / Darmstadt / Chicago / /
Company
SPSS Inc / Control Group / Observation Group / Novartis / Amgen / Ribosepharm / Medac / GlaxoSmithKline / Medical Oncology Working Group / Gemcitabine Group / Instrumentation Laboratory / Sanofi / Lilly Deutschland / LogoMed / Fleming / Bayer / Aventis / Lilly / Merck KG / Mitsubishi Pharma / Gastrointestinal US Intergroup / Intergroup / Janssen Cilag/Ortho Biotech / Breast Cancer International Research Group / Pfizer / Quintiles / AstraZeneca / Antisense Therapeutics / Orion Clinical / Caremark/ Fresenius Kabi GmbH / /
Country
Canada / Germany / Austria / United States / / /
Event
FDA Phase / Product Issues / /
Facility
Asklepios Hospital / Ostalb Hospital / DRK Hospital / Westpfalz Hospital / Medical Outpatient Clinic / Campus Virchow / Barbara Hospital / Henriettenstiftung Hospital / Helios Hospital / Humaine Hospital / Campus Berlin / Campus VirchowKlinikum / Central Hospital / District Hospital / City Hospital / University Hospital / Uckermark Hospital / Marien Hospital / Nord Hospital / German Cancer Research Center / Mayo Clinic / Altstadt Hospital / DeisterWeser Hospital / Carl Thiem Hospital / Israelite Hospital / Bremen Mitte Hospital / DRK City Hospital / Vivantes Hospital / Wald Hospital / Evangelic Hospital / Scientific Institute / /
Holiday
between day / /
IndustryTerm
tomography imaging / magnetic resonance imaging / therapy for colon cancer / control / imaging / study site / treatment of locally advanced or metastatic pancreatic cancer / treatment of advanced pancreatic cancer / treatment of pancreatic cancer / study protocol / treatment of node-positive primary breast cancer / pharmaceutical / treatment of resected pancreatic cancer / /
MedicalCondition
resected pancreatic cancer / JE / normal / postoperative tumor / early breast cancer / II colon cancer / long-term disease / carcinoembryonic antigen/cancer / breast cancer / recurrent disease / adenocarcinoma / tumor / cancer / tumors / thrombocytopenia grade / resectable carcinoma / diseases / infection / ADJUVANT CHEMOTHERAPY WITH GEMCITABINE IN RESECTABLE PANCREATIC CANCER / another malignant disease / lethal cancers / Advanced Disease / gastric cancer / basal cell carcinoma / active infection / leukopenia / metastasis / advanced pancreatic cancer / solid tumors / nausea/vomiting / nausea / thrombocytopenia / alopecia / carcinoma / resectable disease / colon cancer / febrile neutropenia / resectable pancreatic cancer / pancreatic cancer / disease / shock / pain / M0 disease / /
World Health Organization / Winchester DP / Charite´ School of Medicine / German Cancer Society / Department of Medical Oncology and Hematology / German Cancer Research Center / American Medical Association / American Society / /
Person
Jan Langrehr / Klaus Gellert / Joerg Fahlke / Christof Burkart / Axel Hinke / Miyazaki I. An / Marco Niedergethmann / Carl Zuelke / Helmut Oettle / Lars Roll Bernd Doerken / Karsten Ridwelski / Harald Schmalenberg / Hanno Riess / Wolf-Otto Bechstein / Controlled Trial Helmut Oettle / Volker Bartsch / Michael Arning / Ingo Schmidt-Wolf / Visceral Surgery / Klaus Gutberlet / Peter Neuhaus / Roll Bernd Doerken / Pediatric Surgery / Harald Schramm / Erika Kettner / Karin Weigang-Koehler / /
Position
General / Author / Major / representative / investigator / statistician / Corresponding Author / writer / /
ORIGINAL CONTRIBUTION Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer A Randomized Controlled Trial